AbbVie
NYSE:ABBVPharmaNorth Chicago, IL, United States · Est. 2012 · 50,000 employees
Research-driven biopharmaceutical company focused on advanced therapies for complex diseases.
54
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
71
Indications↗
Distinct diseases across all programs
1,506
Clinical Trials↗
All sponsored trials (all statuses)
169
Orange Book Patents
Across 18 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
54 drugs in development
Approved4
Phase 313
Phase 217
Phase 131
Preclinical11
By Therapeutic Area
top 6
Oncology
2740%
Immunology
69%
Ophthalmology
57%
Neurology
46%
Gastroenterology
34%
Psychiatry
34%
R&D Momentum
99/100
Pipeline Velocity
82/100
Trial Completion Rate
86/100
Pipeline Concentration
21/100
Pipeline Freshness
71/100
Strategic Signals
- ↗Active in Metabolic & Endocrine but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Nov 5, 2026
Active, not recruiting
First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants With B-cell Malignancies
Nov 4, 2026
Available
Expanded Access to Venetoclax
Nov 4, 2026
No longer available
Expanded Access to Tavapadon
Nov 3, 2026
Completed
A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
Nov 3, 2026
Active, not recruiting
A Phase 1 Study to Evaluate the Safety and Efficacy of Sequential Administration of AGN-151586 and BOTOX® in Subjects for Treatment of Glabellar Lines (GL)
Nov 2, 2026
8-K
FORM 8-K
Oct 30, 2026
Recruiting
An Operationally Seamless Phase 2b/3, Multicenter, Randomized, Masked, Sham-controlled Study to Evaluate the Efficacy and Safety of Surabgene Lomparvovec (Sura-vec) Delivered Via Suprachoroidal Space (SCS) Injection Targeting Subjects With Diabetic Retinopathy Without Center Involved-Diabetic Macular Edema (CI-DME) (NAAVIGATE)
Oct 30, 2026
Recruiting
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
Oct 30, 2026
Recruiting
A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
Oct 30, 2026
Recruiting
A Phase 1, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-7828, and to Evaluate the Effect of Food on ABBV-7828 Pharmacokinetics in Healthy Adult Subjects
Oct 30, 2026
8-K
8-K
Details
Company Info
Company Overview
$310.0B
Mkt Cap
$54.3B
Revenue
$5.5B
Cash
CEORobert Michael
Founded2012
Employees50,000
HQNorth Chicago, IL, United States
ExchangeNYSE:ABBV
Websiteabbvie.com
LinkedInCompany Page
Therapeutic Focus
OncologyImmunologyMetabolic & EndocrineOtherPsychiatryCardiovascularInfectious DiseaseDermatologyNeurologyGastroenterologyOphthalmologyHematologyNephrologyRespiratoryMusculoskeletalRare Disease
Recent SEC Filings
8-KNov 2, 2026
FORM 8-K
8-KOct 30, 2026
8-K
8-KOct 15, 2026
FORM 8-K
8-KOct 5, 2026
8-K
8-KSep 3, 2026
FORM 8-K
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular(1 drug)
—
—
1
—
—
Cardiovascular(1 drug)
Dermatology(2 drugs)
1
—
—
1
—
Dermatology(2 drugs)
Gastroenterology(3 drugs)
—
—
1
1
2
Gastroenterology(3 drugs)
Hematology(2 drugs)
—
1
—
1
—
Hematology(2 drugs)
Immunology(6 drugs)
2
—
2
4
1
Immunology(6 drugs)
Infectious Disease(1 drug)
1
—
—
—
—
Infectious Disease(1 drug)
Metabolic & Endocrine(2 drugs)
—
—
1
1
—
Metabolic & Endocrine(2 drugs)
Neurology(4 drugs)
—
—
—
2
2
Neurology(4 drugs)
Oncology(27 drugs)
5
22
8
4
—
Oncology(27 drugs)
Ophthalmology(5 drugs)
2
2
1
—
—
Ophthalmology(5 drugs)
Psychiatry(3 drugs)
1
—
2
—
—
Psychiatry(3 drugs)
Respiratory(1 drug)
—
—
1
—
—
Respiratory(1 drug)
Unknown / Other(10 drugs)
—
7
1
1
1
Unknown / Other(10 drugs)
Regulatory
Regulatory Timeline
20255 events
FDADec 18
Vraylar — VRAYLAR
Application NDA204370 (NDA)
FDAOct 10
Rinvoq — RINVOQ LQ
Application NDA218347
FDAOct 10
Rinvoq — RINVOQ
Application NDA211675
FDASep 30
Qulipta — QULIPTA
Application NDA215206
FDASep 9
Zolymbus — ZOLYMBUS
Application NDA217307 (NDA)
202625 events
SECNov 2
FORM 8-K
Accession: 0001104659-26-121322
SECOct 30
8-K
Accession: 0001551152-26-000033
SECOct 15
FORM 8-K
Accession: 0001104659-26-116227
SECOct 5
8-K
Accession: 0001551152-26-000030
FDASep 25
Juvmo — JUVMO
Application NDA220415 (NDA)
SECSep 3
FORM 8-K
Accession: 0001104659-26-104940
SECAug 18
FORM 8-K
Accession: 0001104659-26-098367
SECAug 5
FORM 8-K
Accession: 0001104659-26-091269
SECJul 31
8-K
Accession: 0001551152-26-000023
FDAJul 23
Norvir — NORVIR
Application NDA022417
FDAJul 23
Norvir — NORVIR
Application NDA209512
SECJul 6
8-K
Accession: 0001551152-26-000021
FDAJun 30
Rinvoq — RINVOQ LQ
Application NDA218347
FDAJun 30
Rinvoq — RINVOQ
Application NDA211675
FDAJun 26
Skyrizi — SKYRIZI
Application BLA761105
FDAJun 26
Skyrizi — SKYRIZI
Application BLA761262
SECJun 22
FORM 8-K
Accession: 0001104659-26-076067
FDAJun 12
Skyrizi — SKYRIZI
Application BLA761105
FDAJun 12
Skyrizi — SKYRIZI
Application BLA761262
FDAMay 20
Venclexta — VENCLEXTA
Application NDA208573
FDAMar 18
Skyrizi — SKYRIZI
Application BLA761105
FDAMar 18
Skyrizi — SKYRIZI
Application BLA761262
FDAMar 6
Skyrizi — SKYRIZI
Application BLA761105
FDAMar 6
Skyrizi — SKYRIZI
Application BLA761262
FDAFeb 19
Venclexta — VENCLEXTA
Application NDA208573
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)